| Abstract |
Objective To investigate the clinical effect of hydromorphone patient-controlled analgesia compared with morphine in the treatment of burst pain. Methods 60 patients with burst pain in our hospital from March 2020 to March 2022 were randomly divided into groups. The morphine group was given oral morphine sustained-release tablets for analgesia, and the hydromorphone group was given hydromorphone-controlled analgesia. Compare effects and adverse effects. Results The frequency of burst pain in the hydromorphone group was lower than that in the morphine group at 15min, 30min, 1h, 4h, 12h, 24h, 48h, and 72h after administration, P<0.05. The VAS scores of the hydromorphone group were lower than those of the morphine group at 15min, 30min, 1h, 4h, 12h, 24h, 48h, and 72h after administration, P<0.05. The quality of life in the hydromorphone group at 24h and 72h after administration was higher than that in the morphine group, P<0.05. The incidences of somnolence, nausea, vomiting, and itching in the hydromorphone group were lower than those in the morphine group, P<0.05. Conclusion Hydromorphone patient-controlled analgesia is effective in patients with breakout pain, can effectively relieve pain, and has high safety, and can reduce the occurrence of drowsiness, nausea, vomiting, itching, etc.
|